A citation-based method for searching scientific literature

Anne-Marie Langmach Wegeberg, Christian Stevns Hansen, Adam D Farmer, Jesper Scott Karmisholt, Asbjorn M Drewes, Poul Erik Jakobsen, Birgitte Brock, Christina Brock. United European Gastroenterol J 2020
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
100

Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy.
Tina Vilsbøll, Stephen C Bain, Lawrence A Leiter, Ildiko Lingvay, David Matthews, Rafael Simó, Ida Carøe Helmark, Nelun Wijayasinghe, Michael Larsen. Diabetes Obes Metab 2018
85
100

The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice.
Laurie L Baggio, John R Ussher, Brent A McLean, Xiemin Cao, M Golam Kabir, Erin E Mulvihill, Alexandra S Mighiu, Hangjun Zhang, Andreas Ludwig, Randy J Seeley,[...]. Mol Metab 2017
34
100


Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.
Mark M Smits, Lennart Tonneijck, Marcel H A Muskiet, Trynke Hoekstra, Mark H H Kramer, Michaela Diamant, Daniël H van Raalte. Eur J Endocrinol 2017
24
100


Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
Ildiko Lingvay, Andrei-Mircea Catarig, Juan P Frias, Harish Kumar, Nanna L Lausvig, Carel W le Roux, Desirée Thielke, Adie Viljoen, Rory J McCrimmon. Lancet Diabetes Endocrinol 2019
57
100

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Richard E Pratley, Vanita R Aroda, Ildiko Lingvay, Jörg Lüdemann, Camilla Andreassen, Andrea Navarria, Adie Viljoen. Lancet Diabetes Endocrinol 2018
200
100

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C W Lau, Carel W le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen,[...]. N Engl J Med 2015
697
100

Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial.
Kohei Kaku, Yuichiro Yamada, Hirotaka Watada, Atsuko Abiko, Tomoyuki Nishida, Jeppe Zacho, Arihiro Kiyosue. Diabetes Obes Metab 2018
38
100

Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes.
Julie A Lovshin, Annette Barnie, Ariana DeAlmeida, Alexander Logan, Bernard Zinman, Daniel J Drucker. Diabetes Care 2015
99
100


A low-grade increase of serum pancreatic exocrine enzyme levels by dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes.
Hirotake Tokuyama, Harukiyo Kawamura, Masaki Fujimoto, Kazuki Kobayashi, Mie Nieda, Tetsuya Okazawa, Minoru Takemoto, Fumio Shimada. Diabetes Res Clin Pract 2013
14
100


Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas.
Beatrice Waser, Annika Blank, Eva Karamitopoulou, Aurel Perren, Jean C Reubi. Mod Pathol 2015
52
100




Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database.
V Pizzimenti, A Giandalia, D Cucinotta, G T Russo, M Smits, P M Cutroneo, G Trifirò. J Clin Pharm Ther 2016
12
100

Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.
M E J Lean, R Carraro, N Finer, H Hartvig, M L Lindegaard, S Rössner, L Van Gaal, A Astrup. Int J Obes (Lond) 2014
94
100

Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice.
J H Ellenbroek, H A M Töns, M J A Westerouen van Meeteren, N de Graaf, M A Hanegraaf, T J Rabelink, F Carlotti, E J P de Koning. Diabetologia 2013
37
100

Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study.
Carlo B Giorda, Roberta Picariello, Elisa Nada, Barbara Tartaglino, Lisa Marafetti, Giuseppe Costa, Roberto Gnavi. Lancet Diabetes Endocrinol 2014
33
100

Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist.
Stephen T Buckley, Tine A Bækdal, Andreas Vegge, Stine J Maarbjerg, Charles Pyke, Jonas Ahnfelt-Rønne, Kim G Madsen, Susanne G Schéele, Tomas Alanentalo, Rikke K Kirk,[...]. Sci Transl Med 2018
118
100

Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects.
Jutta Keller, Michael E Trautmann, Harry Haber, Lai San Tham, Tamsin Hunt, Kenneth Mace, Helle Linnebjerg. Regul Pept 2012
38
100

The Discovery and Development of Liraglutide and Semaglutide.
Lotte Bjerre Knudsen, Jesper Lau. Front Endocrinol (Lausanne) 2019
91
100

Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis.
Tito Borner, Jayme L Workinger, Ian C Tinsley, Samantha M Fortin, Lauren M Stein, Oleg G Chepurny, George G Holz, Aleksandra J Wierzba, Dorota Gryko, Ebba Nexø,[...]. Cell Rep 2020
5
100

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial.
Linong Ji, Xiaolin Dong, Yiming Li, Yufeng Li, Soo Lim, Ming Liu, Zu Ning, Søren Rasmussen, Trine Vang Skjøth, Guoyue Yuan,[...]. Diabetes Obes Metab 2021
4
100

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
Andrew J Ahmann, Matthew Capehorn, Guillaume Charpentier, Francesco Dotta, Elena Henkel, Ildiko Lingvay, Anders G Holst, Miriam P Annett, Vanita R Aroda. Diabetes Care 2018
164
100

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Richard Pratley, Aslam Amod, Søren Tetens Hoff, Takashi Kadowaki, Ildiko Lingvay, Michael Nauck, Karen Boje Pedersen, Trine Saugstrup, Juris J Meier. Lancet 2019
128
100

GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting.
Meike Körner, Martin Stöckli, Beatrice Waser, Jean Claude Reubi. J Nucl Med 2007
299
100

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.
Mansoor Husain, Stephen C Bain, Ole K Jeppesen, Ildiko Lingvay, Rasmus Sørrig, Marianne B Treppendahl, Tina Vilsbøll. Diabetes Obes Metab 2020
24
100

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
100

Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
Daisuke Yabe, Jiro Nakamura, Hideaki Kaneto, Srikanth Deenadayalan, Andrea Navarria, Mette Gislum, Nobuya Inagaki. Lancet Diabetes Endocrinol 2020
27
100

The Effect of Bariatric Surgery on Diabetic Retinopathy: Good, Bad, or Both?
Dora M Gorman, Carel W le Roux, Neil G Docherty. Diabetes Metab J 2016
16
100


Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study.
Rebecca A Noel, Daniel K Braun, Ruth E Patterson, Gary L Bloomgren. Diabetes Care 2009
309
100


No QTc Prolongation with Semaglutide: A Thorough QT Study in Healthy Subjects.
Valentin Demmel, Anne Sandberg-Schaal, Jacob B Jacobsen, Georg Golor, Jonas Pettersson, Anne Flint. Diabetes Ther 2018
5
100

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.
Vanita R Aroda, Julio Rosenstock, Yasuo Terauchi, Yuksel Altuntas, Nebojsa M Lalic, Enrique C Morales Villegas, Ole K Jeppesen, Erik Christiansen, Christin L Hertz, Martin Haluzík. Diabetes Care 2019
86
100

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
Sonal Singh, Hsien-Yen Chang, Thomas M Richards, Jonathan P Weiner, Jeanne M Clark, Jodi B Segal. JAMA Intern Med 2013
255
100


The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.
Niels C B Nyborg, Anne-Marie Mølck, Lars W Madsen, Lotte Bjerre Knudsen. Diabetes 2012
103
100

Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
Apostolos Tsapas, Ioannis Avgerinos, Thomas Karagiannis, Konstantinos Malandris, Apostolos Manolopoulos, Panagiotis Andreadis, Aris Liakos, David R Matthews, Eleni Bekiari. Ann Intern Med 2020
27
100

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Christopher Sorli, Shin-Ichi Harashima, George M Tsoukas, Jeffrey Unger, Julie Derving Karsbøl, Thomas Hansen, Stephen C Bain. Lancet Diabetes Endocrinol 2017
163
100

Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.
Olivia R Ghosh-Swaby, Shaun G Goodman, Lawrence A Leiter, Alice Cheng, Kim A Connelly, David Fitchett, Peter Jüni, Michael E Farkouh, Jacob A Udell. Lancet Diabetes Endocrinol 2020
37
100

Effects of glucagon-like peptide-1 receptor agonists on fluid intake in healthy volunteers.
Bettina Winzeler, Ismael da Conceição, Julie Refardt, Clara O Sailer, Gilles Dutilh, Mirjam Christ-Crain. Endocrine 2020
2
100


Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials.
Besmir Nreu, Ilaria Dicembrini, Federico Tinti, Edoardo Mannucci, Matteo Monami. Diabetes Res Clin Pract 2020
5
100

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
Bernard Zinman, Vaishali Bhosekar, Robert Busch, Ingrid Holst, Bernhard Ludvik, Desirée Thielke, James Thrasher, Vincent Woo, Athena Philis-Tsimikas. Lancet Diabetes Endocrinol 2019
71
100

Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study.
M Wenten, J A Gaebler, M Hussein, E M Pelletier, D B Smith, P Girase, R A Noel, D K Braun, G L Bloomgren. Diabet Med 2012
66
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.